Springe direkt zu Inhalt

Oral presentations/posters without abstracts/Vorträge/Poster ohne Abstract

  • R. Michelet.
    Uso de la farmacometría en casos complejos de bioequivalencia.
    Workshop: Farmacometría y modelamiento en el ecosistema farmacéutico nacional, Santiago, Chile, 04 December 2023.

  • F. Klima.
    Early survival prediction framework for autologous CAR-T cells using PK/PD modelling.
    19es Journées du Groupe de Pharmaclogie Clinique Oncologique, Strasbourg, France, 16-17 November 2023.

  • R. Michelet.
    The future: Can PopPK modelling and simulation support generic development?
    Bioequivalence: New trends and recent discussions, workshop for 25 years anniversary. Socratec R&D, Frankfurt, Germany, 11 October 2023.

  • R. Michelet.
    Model-Based Pharmacokinetic/Pharmacodynamic prediction of FIH approach.
    German Pharmacology and Toxicology Summit, Ulm, Germany, 06-08 March 2023.

  • C. Kloft.
    Translational Pharmacometrics: Advancing precision dosing through innovative data science.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Tübingen, Germany, 07-10 October 2023.

  • C. Kloft.
    CAR-T Zelltherapie: Was kann die Klinische Pharmazie zum Erfolg beitragen.
    Deutsche Pharmazeutische Gesellschaft (DPhG) Landesgruppe Berlin-Brandenburg, Berlin, Germany, 06 July 2023.

  • R. Michelet.
    Beyond popPK models.
    2nd Educational Pharmacometrics Summer Symposium, A Coruña, Spain, 27 June 2023.

  • C. Kloft.
    CAR-T Zelltherapie: Was kann die Klinische Pharmazie zum Erfolg beitragen.
    Deutsche Pharmazeutische Gesellschaft (DPhG) Landesgruppe Schleswig-Holstein, Kiel, Germany, 06 June 2023.

  • M. Andersson.
    Beyond the standard ratio: Quantitative exploration of the effect of piperacillin with varying tazobactam concentrations.
    International Society of Anti-Infective Pharmacology (ISAP), Copenhagen, Denmark, 14 April 2023.

  • L.B.S. Aulin.
    Translational PK/PD modelling in the context of Flagellin Aerosol therapy as an Immunomodulatory adjunct to the antibiotic treatment of drug-Resistant bacterial pneumonia (FAIR).
    Stockholm Uppsala Pharmacometrics (SUP) fall meeting, Uppsala, Sweden, 13October 2022.

  • C. Kloft.
    Therapeutic Drug Monitoring for oral anticancer therapies: ON-TARGET study.
    35th Deutscher Krebskongress (DKK), Berlin, Germany, 16 November 2022.

  • C. Kloft.
    Biomarker monitoring and pharmacometric modelling to optimise anticancer therapy.
    46th International society of oncology and biomarkers (ISOBM) Congress, Bled, Slovenia, 16 October 2022.

  • R. Michelet.
    Development and application of a translational modelling and simulation platform for flagellin PK/PD in the context of Flagellin Aerosol therapy as an Immunomodulatory adjunct to the antibiotic treatment of drug-Resistant bacterial pneumonia (FAIR).
    4th Iberoamerican Pharmacometrics Network Congress (RedIF), Porto Alegre, Brazil, 5 October 2022.

  • A.M. Mc Laughlin.
    Developing an endoxifen PK prediction model including CYP2D6 allelic percentage activity in the CEPAM meta-analysis.
    Pharmacogenomics Global Research Network-Research in Progress meeting, virtual, 08 July 2022.

  • N. Zimmermann.
    Integrated in vitro approach to understand the exposure-effect relationship of fosfomycin against Escherichia coli.
    International Society of Anti-Infective Pharmacology (ISAP), Lisbon, Portugal, 22 April 2022.

  • A.M. Mc Laughlin.
    Early survival prediction framework in CD19-specific CAR-T cell immunotherapy using a quantitative systems pharmacology model.
    ASCPT Webinar: Quantitative Clinical Pharmacology Approaches Towards Understanding Exposure and Response of CAR-T Cell Therapies, Virtual, 15 December 2021.

  • C. Kloft.
    Therapeutic Drug Monitoring in Oncology – Status quo.
    Annual meeting of the German, Austrian, and Swiss Societies of Hematology and Medical Oncology (DGHO), Berlin, 01-04 October 2021.

  • R. Michelet.
    The use of translational modelling and simulation to assess immunomodulator–drug Interactions: lessons learned and way forward.
    Annual Meeting of the Deutsche Pharmazeutische Gesellschaft (DPhG), Virtual, 28 September - 01 October 2021

  • D. Seeler, N. Grdseloff, C. J. Rödel, C. Kloft, S. Abdelilah-Seyfried, W. Huisinga.
    Towards understanding vascular (dys)regulation by integrating endothelial cell morphology, blood vessel geometry and blood flow response signaling: Development of geometric model.
    19th conference on Computational Methods in Systems Biology (CMSB), Bordeaux, France/online (hybrid), 22-24 September 2021.

  • J. Seeger.
    Quantification of persister formation of Escherichia coli leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling.
    International Society of Anti-Infective Pharmacology (ISAP) Virtual Meeting, 26 May 2021.

  • A. Mueller-Schoell.
    Towards model-informed precision dosing of targeted anticancer drugs.
    Melanoma Medical Oncology Research Seminar, MD Anderson Cancer Center, Houston, Texas, United States of America, Virtual, 03 May 2021.

  • A. Mueller-Schoell
    A quantitative systems pharmacology model of four CAR-T cell phenotypes and CD19-positive metabolic tumour volume elucidates sources of the large pharmacokinetic variability.
    European Organisation for Research and Therapy of Cancer – Pharmacology and Molecular Mechanisms (EORTC-PAMM) Spring Meeting, Virtual, 21-22 April 2021.

  • R. Michelet.
    What about antimicrobial resistance? Tackling ‘the other pandemic’.
    Yearly symposium of the Internationales Begegnungszentrum der Wissenschaft (IBZ), Berlin, 12 December 2020.

  • C. Kloft.
    Neue Chancen zur Therapieoptimierung bei Kindern durch Pharmakometrie.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Magdeburg, Germany, 02 September 2020.

  • C. Kloft.
    Viele Patienten, eine Dosis? Die Rolle des Therapeutischen Drug Monitoring (TDM) bei der oralen Tumortherapie.
    German Cancer Congress 2020, Berlin, 20 Februrary 2020.

  • R. Michelet.
    Enfoque farmacometrico en la investigación de fármacos antiinfecciosos: desde los estudios in vitro a los estudios in vivo.
    Simposio de Farmacometría: Nuevas Estrategias Para El Desarrollo De Medicamentos Y La Optimización Farmacoterapéutica, Universidad de Santiago de Chile, Santiago de Chile, 18 December 2019.

  • A. Mueller-Schoell.
    Pharmacometric modelling & simulation for an increased understanding of CAR-T cell therapy in cancer.
    MEDICA LABMED Forum, Duesseldorf, 21 November 2019.

  • F.W. Ojara.
    Exposure-response pharmacometric modelling and simulation to improve treatment outcome in advanced NSCLC.
    MEDICA LABMED Forum, Duesseldorf, 21 November 2019.

  • R. Michelet.
    The use of PBPK modeling across the pediatric age range using propofol as a case.
    10th Annual Simcyp Virtual Seminar on Applications of Population-based IVIVE and PBPK, 13 November 2019.

  • C. Maier, J. de Wiljes, N. Hartung, C. Kloft,  W. Huisinga.
    Reinforcement learning for individualised dosing policies in oncology.
    6th International Conference on Continuous Optimization (ICCOPT), Berlin, Germany, 05-08 August 2019.

  • C. Kloft.
    Von der Maus zum Menschen –  Wie lassen sich Ergebnisse aus Tierversuchen auf den Menschen übertragen?
    Long Night of Science, Berlin, Germany, 15 June 2019.

  • J. Seeger.
    Bakterien unter Kontrolle?! Mythen und Wahrheiten zur Antibiotikatherapie
    Long Night of Science, Berlin, Germany, 15 June 2019.

  • A.M. Grišić.
    Influence of pregnancy on clearance of therapeutic monoclonal antibodies: Pharmacometric analysis of infliximab in inflammatory bowel disease.
    23rd Pharmacokinetics/Pharmacodynamics(PK/PD) Expert Meeting, Friedrichroda, Germany, 09-11 May 2019.

  • R. Michelet.
    Applying the general pharmacodynamic interaction model on high-throughput combinatorial data to identify drug
    combinations overcoming multi-drug-resistance.
    Novel Antimicrobials and AMR Diagnostics 2019,
    Academic innovations session, Berlin, Germany, 14 March 2019.

  • P. Simon, D. Petroff, R. Werdehausen, L. Ehmann, D. Busse, D. Hochstädt, A. Dietrich, C. Kloft, M. Zeitlinger, C. Dorn, F. Kees, S.N. Stehr, H. Wrigge.
    Modellierung von Linezoliddosierungen anhand von Plasma- und Gewebespiegel normalgewichtiger und adipöser Patienten.
    33. Wissenschaftliche Arbeitstage der DGAI, Würzburg, Germany, 15 February 2019.

  • C. Kloft.
    Pharmacometrics: Analysing and understanding variability and uncertainty.
    SFB1294 Colloquia, Potsdam, Germany, 01 February 2019.

  • C. Kloft.
    Neue Chancen zur Therapieoptimierung bei Kindern durch Pharmakometrie.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Regensburg, Germany, 23 January 2019.

  • R. Michelet.
    Clinical Pharmacy at FU Berlin: to foster rational use of medicine.
    Ernst-Reuter Tag, Berlin, Germany, 04 December 2018.

  • C. Kloft.
    No medicine for the youngest - how pharmacometrics can contribute to better therapies in congenital adrenal hyperplasia.
    The Use Of Modeling And Simulation Tools In Pediatric Drug Research – Mini-Symposium, Ghent, Belgium, 29 August 2018.

  • C. Kloft.
    Pharmacometrics – for better decision-making in anticancer drug development and therapeutic use.
    33rd German Cancer Congress, Berlin, Germany, 21 February 2018.

  • C. Kloft.
    Translational pharmacometric approaches in oncology.
    Arbeitsgemeinschaft Internistische Onkologie – Autumn Meeting, Berlin, Germany, 17 November 2017.

  • C. Kloft.
    Arzneimitteltherapie in der Schwangerschaft und bei Neugeborenen – Wie kann ich gut beraten.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Koblenz, Germany, 03 July 2017.

  • C. Kloft.
    Moderne Entscheidungshilfen in der Arzneimitteltherapie – Von der Wissenschaft zur Praxis.
    Arzneimittelkommission der Deutschen Apothekerschaft (AMK), Berlin, Germany, 31 May 2017.

  • C. Kloft.
    Pharmakotherapie im Kindesalter – Grundlagen und pharmazeutische Praxis.
    Pharmakotherapeutisches Colloquium, Berlin, Germany, 15 February 2017.

  • L. Ehmann.
    Making use of modelling and simulations: Exploring standard meropenem dosing in intensive care patients.
    Tag der Pharmazie, Berlin, Germany, 01 July 2016.

  • J. M. Borghardt.
    Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.
    20th Pharmacokinetics/Pharmacodynamics (PK/PD) Expert Meeting, Berlin, Germany, 14-16 April 2016.

  • C. Kloft.
    Modelling of phenotypic resistance.
    32nd German Cancer Congress, Berlin, Germany, 25 February 2016.

  • C. Kloft.
    Arzneimitteltherapie in der Schwangerschaft und bei Neugeborenen.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Erlangen, Germany, 04 February 2016.

  • Z.P. Parra-Guillen.
    Modelling discrete data via DDMoRe: a new framework for modelling & simulation.
    VI Jornadas de simulacion y modelizacion en biomedicina, Madrid, Spain, 27 November 2015.

  • J.M. Borghardt, B. Weber.
    Characterizing the pulmonary Pharmacokinetics of Inhaled Drugs in Humans.
    The Academy of Pharmaceutical Sciences. Modulating the pharmacokinetics of inhaled drugs.
    Glaxo Smith Kline, Stevenage, United Kingdom, 05 November 2015.

  • A.K. Strunz, C. Eickhoff, L. Botermann, M. Felberg, U. Müller, M. Schulz.
    The project PRIMA – Primärsystem-Integration des Medikationsplans mit Akzeptanzuntersuchung.
    17. Jahreskongress für Klinische Pharmakologie. Köln, Germany, 01-02 October 2015. [www.egms.de/static/en/meetings/vklipha2015/15vklipha34.shtml], (2015).

  • C. Kloft.
    Overview on population pharmacokinetic modelling and pharmacokinetic-pharmacodynamic relations, the idea of modelling, different kinds of models, model components, use of modelling.
    EU-NTC Assessors Training Workshop, Bonn, Germany, 11 September 2015.

  • C. Kloft, L. Botermann.
    Medikationsmanagement.
    Informationsveranstaltung des Berliner Apotheker-Vereins und der Apothekerkammer Berlin, Berlin, Germany, 29 June 2015.

  • C. Kloft.
    Zu Risiken und Nebenwirkungen… .
    Festvortrag zum Tag der Pharmazie, Universität Hamburg, Hamburg, Germany, 17 June 2015.

  • L. Botermann
    Morgens 2 – mittags ½ - abends 1 ½ - Wie behalte ich den Überblick über meine Medikamente.
    Lange Nacht der Wissenschaft, Institut für Pharmazie. Freie Universität Berlin, Berlin, Germany, 13 June 2015.

  • C. Kloft.
    Pharmakometrie: Wie sie zur besseren Arzneimitteltherapie bei Schwangeren und Neugeborenen beitragen kann.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Tübingen, Germany, 19 May 2015.

  • C. Kloft.
    Arzneimittel bei Schwangerschaft – Wie kann ich gut beraten.
    Pharmakotherapeutisches Colloquium, Berlin, Germany, 11 February 2015

  • I.K. Minichmayr, C. Weiser.
    In vitro and in silico approaches to improve clinical drug monitoring and drug development.
    Clinical Microdialysis Symposium Berlin-Buch, Berlin, Germany, 12 December 2014.

  • C. Kloft.
    Arzneimitteltherapie während der Schwangerschaft – Was ist möglich, wo ist Vorsicht geboten.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Hannover, Germany, 20 November 2014.

  • D. Kauzor.
    Are paediatric CAH patients sufficiently treated with individually compounded capsules?.
    6th Conference of the European Paediatric Formulation Initiative (EUPFI), Athens, Greece, 18 September 2014.

  • A. Henrich, C. Kloft.
    Damit nicht mehr alles grau erscheint - Wichtiges in der Behandlung von Depressionen.
    Lange Nacht der Wissenschaften, Berlin, Germany, 10 May 2014.

  • C. Kloft.
    Innovative Tumortherapien: Grundlagen und pharmazeutische Praxis.
    Pharmakotherapeutisches Colloquium, Berlin, Germany, 26 February 2014.

  • C. Kloft.
    Introduction to population pharmacokinetic analysis – concept and methodology.
    Charité, University Hospital Berlin, Berlin, Germany, 14 January 2014.

  • C. Kloft.
    Alzheimertherapeutika: Grundlagen und pharmazeutische Praxis.
    Pharmakotherapeutisches Colloquium, Berlin, Germany, 13.02.2013.

  • C. Kloft.
    Clinical microdialysis and physiology-motivated population modelling.
    7th International Symposium on Microdialysis, Poitiers, France, 24.05.2013.


  • C. Kloft.
    Dosierungen von Arzneimitteln bei (HIV-)Schwangeren und Neugeborenen.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Braunschweig, Germany, 11.07.2013.

  • C. Kloft.
    Quantifying the impact of nevirapine-based prophylaxis strategies to prevent
    mother-to-child transmission of HIV-1 using the population approach.
    11th European Association of Clinical Pharmacology and Therapeutics (EACPT) Congress, Geneva, Switzerland, 30.08.2013.

  • J. Kuss.
    Forschungsverbünde auf dem Gebiet der Klinischen Pharmazie an Hochschulstandorten in Deutschland.
    Deutsche Pharmazeutische Gesellschaft (DPhG), Bonn, Germany, 23.11.2013.

  • C. Kloft.
    Arzneimitteltherapie bei Demenzpatienten.
    Lange Nacht der Wissenschaften, Berlin, 02.06.2012.

  • A. Schaeftlein.
    Verführerische Müdemacher-Schlafmittel im Alter.
    Lange Nacht der Wissenschaften, Berlin, 02.06.2012.

  • C. Kloft.
    Pharmacometrics and systems biology: is there an intersection?
    Annual Meeting of the Central European Society of Anticancer Research (CESAR), Essen, Germany, 28.-30.06.2012.